***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 DECEMBER 2024**

Following is the advice of the Pharmaceutical Benefits Advisory Committee (PBAC) concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Carmellose with glycerin | The sponsor requested the delisting of Optive® (carmellose with glycerin) from the Pharmaceutical Benefits Scheme (PBS).  The PBAC noted there are alternative lubricating eye drops available. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Cefepime | The sponsor requested the delisting of Cefepime Kabi(cefepime 1 gram and 2 gram injections) from the PBS.  The PBAC noted that cefepime is an important medicine for the treatment of febrile neutropenia and most of its use is in public hospitals and therefore not on the PBS. The PBAC considered that while delisting cefepime from the PBS would likely not significantly affect patient access, discontinuation of the product would cause problems in clinical practice. The PBAC advised the delisting of this product may result in an unmet clinical need and requested that the Department seek to retain these products on the PBS. |

Brendon Wheatley

Director (A/g), PBAC Governance

Office of Health Technology Assessment

Technology Assessment and Access Division

20 November 2024